Diagnostic markers of cognitive impairments, kits and uses thereof
AssigneeADventDX
InventorsNicolas Pelletier, Philippe Compagnone, Nathalie Compagnone
Life of this patent
Estimating the term…
Abstract
The invention relates to in vitro or ex vivo methods for assessing the cognitive function of a subject in the context of the prevention of neurodegenerative diseases. A particular method comprises a step of associating a subject to a cognitive status selected from healthy cognitive status, Subjective Cognitive Impairment, Mild Cognitive Impairment and neurodegenerative disease, and the association of cognitive status results from the evaluation of glycosylated MCSF and CCR2 expressed at the surface of PBMC in a biological sample from the subject. The present invention also provides kits suitable for implementing such methods.
Claims21
An in vitro or ex vivo method for assessing the cognitive function of a subject, wherein said method comprises a step of associating said subject to a cognitive status selected from Subjective Cognitive Impairment (SCI) and Mild Cognitive Impairment (MCI), and wherein said association results from the evaluation of glycosylated MCSF (Macrophage Colony Stimulating Factor) in a blood sample deprived of red blood cells from the subject, evaluation of CCR2 expressed on the surface of peripheral blood mononuclear cells (PBMCs) in a blood sample from the subject, and of at least one of IL-3 and CCL18 (PARC) in a blood sample from the subject, wherein the method comprises separating PBMCs from plasma in the blood sample and said evaluation step comprises detecting the presence of a marker, comparing the concentration of a marker to a reference value and/or comparing markers.
An in vitro or ex vivo method for assessing the cognitive function of a subject, wherein said method comprises a step a) of determining whether said subject is suffering of Subjective Cognitive Impairment (SCI), said step a) comprising evaluating at least CCR2 expressed on the surface of PBMCs in a blood sample from the subject, and if the subject is not identified as suffering of SCI, a step b) of determining whether said subject is suffering of Mild Cognitive Impairment (MCI) said step b) comprising evaluating glycosylated MCSF together with CCL18, and optionally together with CCR2, in a sample deprived of red blood cells obtained from the blood sample from the subject, and if the subject is not identified as suffering of MCI, a step c) of determining whether said subject is suffering of AD, said step c) comprising evaluating CCL18 (PARC) and IL3 in a biological sample deprived of red blood cells from the subject, wherein the method comprises separating PBMCs from plasma obtained from the blood sample, and the evaluation step comprises determining the presence of a marker, comparing the concentration of a marker to a reference value and/or comparing markers.
A kit suitable for implementing a method for assessing the cognitive function of a subject, or for determining whether a subject is suffering of a cognitive impairment or of a neurodegenerative disease, or is at risk of developing such a neurodegenerative disease, wherein the kit comprises a capture agent binding specifically glycosylated MCSF, a capture agent binding specifically CCR2 expressed at the surface of PBMCs, and a capture agent binding at least one of IL-3 and CCL18 (PARC);
- and instructions for carrying out the method.
A kit for assessing whether a subject suffering of SCI or MCI is at risk of developing AD, wherein the kit comprises a capture agent binding specifically CCR2 expressed at the surface of PBMCs and a capture agent binding specifically glycosylated MCSF.
Dependencies are inferred from the claim text.